

# Bulletin #156: COVID-19 Information

## July 15, 2021



### In This Issue: COVID-19 Bulletin

[Reminder: Path to Green Phase 2 visitor guidelines](#)

[Screening criteria for staff and physicians](#)

[Myocarditis and pericarditis following vaccination](#)

[COVID-19 dashboard data from July 13](#)

### COVID-19 Bulletin

#### [Reminder: Path to Green Phase 2 visitor guidelines](#)

The new visitor guidelines for Horizon facilities are effective today, July 15. For more information, please review and share the Standard Operating Procedures on [Skyline](#) and [key messages](#).

#### [Screening criteria for staff and physicians](#)

Please review the current screening questions for employees and physicians [here](#). All posters are available on the [Coronavirus Skyline page](#).

If you answer yes to any of the questions, you are not to enter the facility. You must contact Employee Health at 1-833-978-2580 for further screening and possible referral to a COVID-19 assessment centre. Patient and visitor questions can be found [here](#).

Employee Health and Wellness is available Monday to Friday, from 8 a.m. to 4 p.m. to answer any questions or concerns.

#### [Myocarditis and pericarditis following vaccination](#)

On June 30, 2021, Health Canada updated the product monographs on the use of the mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to include very rare reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination.

There are many potential causes of myocarditis and pericarditis, including viral infections. It can also occur as a complication in people who are infected with SARS-CoV-2, the COVID-19 virus.

A small number of cases of myocarditis and / or pericarditis following immunization with mRNA COVID-19 vaccines have been reported in Canada and internationally.

Thus far, cases have been reported more frequently in adolescents and younger adults under 30 years of age, more often in males

## Bulletin #156: COVID-19 Information

July 15, 2021

than in females, and more frequently after a second dose. The majority of cases have been mild, and individuals have recovered quickly.

People who are offered a mRNA COVID-19 vaccine should be informed of the very rare risk of myocarditis and / or pericarditis following immunization and should be advised to seek immediate medical attention if they develop symptoms, which may include chest pain, shortness of breath, or the feeling of a fast, pounding or fluttering heartbeat.

Cases typically occur within a week after the receipt of an mRNA vaccine dose, more commonly after a second dose. Any potential cases occurring within a month of vaccination should be reported as an adverse event and investigated with medical assessment.

As a precaution, NACI recommends that individuals who experienced myocarditis and / or pericarditis after a first dose of an mRNA vaccine should wait to get their second dose until more information is available. Having a prior medical history of myocarditis and / or pericarditis does not preclude getting a first dose of mRNA.

Updated information can be found on the GNB COVID-19 vaccine website Health Professional section [here](#).

